BriaCell Therapeutics (BCT) Price & Analysis

Compare

89 Followers

BCT Stock Chart & Stats

C$16.54

-C$0.02(-3.08%)

At close: Jan 08 4:00 PM EST

C$16.54

-C$0.02(-3.08%)

Day’s Range― - ―

52-Week RangeC$8.40 - C$274.68

Previous CloseN/A

Volume105.15K

Average Volume (3M)3.11K

Market Cap

C$31.16M

Enterprise Value-C$6.43M

Total Cash (Recent Filing)C$12.46M

Total Debt (Recent Filing)C$0.00

Price to Earnings (P/E)―

Beta2.09

Next Earnings

Dec 10, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-5.90

Shares Outstanding1,883,906

10 Day Avg. Volume3,860

30 Day Avg. Volume3,110

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$56.09

Price Target Upside239.12% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressBria-IMT improves progression-free survival in delayed-type hypersensitivity positive patients, showing statistically significant benefits across all treatment arms.

Financial OutlookShare consolidation and $15M equity raise announced; adjusting PT to $40 from $32.

Safety ProfileBria-IMT's safety and tolerability profile remains favorable, with no interstitial lung disease or CNS complications observed.

Bears Say

Financial PerformanceShare consolidation and $15M equity raise announced; adjusting PT to $40 from $32.

BriaCell Therapeutics News

BriaCell presents Phase 3 clinical biomarker data at ESMO 2025

BriaCell (BCTX) Therapeutics announces encouraging clinical biomarker data in its ongoing pivotal Phase 3 study of Bria-IMT plus...

17h ago

BCTX

BriaCell to present clinical biomarker data of Phase 3 Bria-IMT study

BriaCell (BCTX) Therapeutics will be presenting clinical biomarker data of its ongoing pivotal Phase 3 study of Bria-IMT...

8d ago

BCTX

BriaCell Reports Promising Phase 3 Data in Metastatic Breast Cancer Study

An update from BriaCell Therapeutics ( ($TSE:BCT) ) is now available. BriaCell Therapeutics has announced promising clinical biomarker...

17h ago

BCTX

Promising Phase 3 Results for BriaCell’s Bria-IMT in Metastatic Breast Cancer

BriaCell Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from...

8d ago

BCTX

BriaCell Reports Positive Phase 3 Biomarker Data for Metastatic Breast Cancer Treatment

BriaCell Therapeutics ( ($TSE:BCT) ) has issued an update. BriaCell Therapeutics announced positive clinical biomarker data from its...

8d ago

BCTX

BriaCell to Present Innovative Cancer Vaccine Data at SITC 2025

BriaCell Therapeutics ( ($TSE:BCT) ) has shared an announcement. BriaCell Therapeutics Corp. announced that it will present preclinical...

18d ago

BCTX

BriaCell Therapeutics: Strategic Advancements and Financial Strength Drive Buy Rating

Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on BriaCell Therapeutics. The associated price target...

2M ago

BCTX

BriaCell’s Bria-OTS+ Platform Validated in Cancer Journal

BriaCell Therapeutics ( ($TSE:BCT) ) just unveiled an announcement. BriaCell Therapeutics has announced the validation of its Bria-OTS+...

2M ago

BCTX

BriaCell’s Bria-OTS mechanism of action study published by JCI Insight

BriaCell (BCTX) Therapeutics announced the publication of the mechanism of action of its next generation personalized off-the-shelf immunotherapy....

2M ago

BCTX

BriaCell Secures $2 Million Grant for Prostate Cancer Immunotherapy

BriaCell Therapeutics ( ($TSE:BCT) ) just unveiled an update. BriaCell Therapeutics has been awarded a $2 million grant...

2M ago

BCTX

BriaCell awarded $2M NCI grant to advance Bria-POS+

BriaCell (BCTX) Therapeutics announces that the National Cancer Institute, NCI, the United States federal government’s principal agency for...

2M ago

BCTX

BriaCell Therapeutics trading halted, news pending

19:50 EDT BriaCell (BCTX) Therapeutics trading halted, news pending Published first on TheFly – the ultimate source for...

2M ago

BCTX

BriaCell Announces Share Consolidation to Meet Nasdaq Requirements

BriaCell Therapeutics ( ($TSE:BCT) ) has issued an announcement. BriaCell Therapeutics announced a share consolidation plan, converting every...

2M ago

BCTX

BriaCell to effect 1-for-10 share consolidation on August 25

BriaCell (BCTX) Therapeutics announced that the Company’s board of directors has approved the consolidation of the Company’s issued...

2M ago

BCTX

BCT FAQ

What was BriaCell Therapeutics Corp’s price range in the past 12 months?

BriaCell Therapeutics Corp lowest stock price was C$8.40 and its highest was C$274.68 in the past 12 months.

What is BriaCell Therapeutics Corp’s market cap?

BriaCell Therapeutics Corp’s market cap is C$31.16M.

When is BriaCell Therapeutics Corp’s upcoming earnings report date?

BriaCell Therapeutics Corp’s upcoming earnings report date is Dec 10, 2025 which is in 50 days.

How were BriaCell Therapeutics Corp’s earnings last quarter?

BriaCell Therapeutics Corp released its earnings results on Oct 15, 2025. The company reported -C$5.902 earnings per share for the quarter, missing the consensus estimate of N/A by -C$5.902.

Is BriaCell Therapeutics Corp overvalued?

According to Wall Street analysts BriaCell Therapeutics Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does BriaCell Therapeutics Corp pay dividends?

BriaCell Therapeutics Corp does not currently pay dividends.

What is BriaCell Therapeutics Corp’s EPS estimate?

BriaCell Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does BriaCell Therapeutics Corp have?

BriaCell Therapeutics Corp has 1,883,906 shares outstanding.

What happened to BriaCell Therapeutics Corp’s price movement after its last earnings report?

BriaCell Therapeutics Corp reported an EPS of -C$5.902 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.182%.

Which hedge fund is a major shareholder of BriaCell Therapeutics Corp?

Currently, no hedge funds are holding shares in TSE:BCT

BriaCell Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-342.38%

Trailing 12-Months

Asset Growth

268.97%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

BriaCell Therapeutics Corp

BriaCell Therapeutics (BCT) is a biotechnology company focused on developing targeted immunotherapy treatments for cancer. Primarily operating in the healthcare and pharmaceuticals sector, BriaCell is dedicated to improving patient outcomes through its innovative cancer treatment solutions, with a particular emphasis on breast cancer. The company's core product candidates include Bria-IMT, a clinical-stage immunotherapy aimed at harnessing the body's immune system to fight cancer cells.

BriaCell Therapeutics (BCT) Earnings & Revenues

Historic Earnings Reports

BCT Stock 12 Month Forecast

Average Price Target

C$56.09

▲(239.12% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"C$9","434":"C$434","115.25":"C$115.3","221.5":"C$221.5","327.75":"C$327.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56.09398,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$56.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56.09,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$56.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56.09398,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$56.09</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,115.25,221.5,327.75,434],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.3,13.822613846153846,17.345227692307695,20.86784153846154,24.390455384615386,27.91306923076923,31.43568307692308,34.95829692307693,38.480910769230775,42.00352461538462,45.526138461538466,49.04875230769231,52.57136615384616,{"y":56.09398,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.3,13.822307692307692,17.344615384615388,20.86692307692308,24.38923076923077,27.911538461538463,31.433846153846158,34.95615384615385,38.478461538461545,42.00076923076924,45.52307692307693,49.04538461538462,52.56769230769231,{"y":56.09,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.3,13.822613846153846,17.345227692307695,20.86784153846154,24.390455384615386,27.91306923076923,31.43568307692308,34.95829692307693,38.480910769230775,42.00352461538462,45.526138461538466,49.04875230769231,52.57136615384616,{"y":56.09398,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":433.5,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":343.5,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.75,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":234,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.3,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":52.1,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":50,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":57,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":46.2,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":40,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >